Geron Corp GERN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GERN is a good fit for your portfolio.
News
-
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Geron to Participate at Upcoming Investor Conferences in April
-
Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
-
Geron's stock soars 95% after FDA advisory panel votes in favor of blood-disorder drug
-
Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS
-
Thinking about buying stock in Onespan, Avinger, Lithium Americas, Geron, or Femasys?
-
Thinking about buying stock in Ocean Biomedical, CASI Pharmaceuticals, Cardiol Therapeutics, Geron, or Rocket Pharmaceuticals?
-
Thinking about buying stock in Minim, GameSquare, Laser Photonics, Geron, or Mind Medicine?
Trading Information
- Previous Close Price
- $3.50
- Day Range
- $3.51–3.71
- 52-Week Range
- $1.64–4.05
- Bid/Ask
- $3.58 / $3.70
- Market Cap
- $2.11 Bil
- Volume/Avg
- 173 / 13.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8,626.51
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 141
- Website
- https://www.geron.com
Comparables
Valuation
|
Metric
|
GERN
|
PLRX
|
KROS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 7.87 | 1.51 | 5.39 |
Price/Sales | 8,626.51 | 442.25 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
GERN
PLRX
KROS
Financial Strength
|
Metric
|
GERN
|
PLRX
|
KROS
|
|---|---|---|---|
Quick Ratio | 3.10 | 17.43 | 13.63 |
Current Ratio | 3.16 | 17.72 | 14.25 |
Interest Coverage | −23.34 | −145.34 | — |
Quick Ratio
GERN
PLRX
KROS
Profitability
|
Metric
|
GERN
|
PLRX
|
KROS
|
|---|---|---|---|
Return on Assets (Normalized) | −45.05% | −22.68% | −35.62% |
Return on Equity (Normalized) | −66.61% | −24.50% | −39.15% |
Return on Invested Capital (Normalized) | −56.50% | −28.46% | −41.95% |
Return on Assets
GERN
PLRX
KROS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dgcvfzvlg | Byd | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gvdgfhdz | Dhwsnjy | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pzzywrwy | Xwnzzt | $99.5 Bil | |
MRNA
| Moderna Inc | Jwkmgrrl | Njxm | $38.8 Bil | |
ARGX
| argenx SE ADR | Skrfyzcb | Crh | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Jfgqgyty | Ynbm | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Nmzvplhg | Lnjgyn | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kykzhwr | Lbhmvb | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xfqgnxxqc | Fzccxg | $12.5 Bil | |
INCY
| Incyte Corp | Qbnqckzxj | Rncsdn | $11.6 Bil |